Venture capital investments in the economy’s pharma and biotech sector is booming, according to Venture Pulse, a quarterly report published by KPMG Private Enterprise. Globally, VC investment has risen for the second straight quarter, although more money went into far fewer deals.Total VC investment reached $73.2 billion in the third quarter with pharma and biotech drawing $31 billion of that. That was up from $70 billion in the second quarter, but the number of deals dropped to 4,681 from 5,674 the sixth straight quarter of decline and the lowest total since the fourth quarter of 2013.
The United States had $37.8 billion in investment, out of $40 billion in the Americas for the quarter. VC investment in Asia-Pacific was $21.1 million in the quarter, up from $17.2 billion in the second quarter. Investment in Europe in $12.1 billion, which the publication describe as a new high.
